Table 1 Clinical characteristics of RA patients stratified by DAS28-ESR (N = 997).

From: Association between systemic immune-inflammation index and disease activity score 28 in patients with rheumatoid arthritis: a cross-sectional study

Characteristics

Total

DSA28ESR

P value

< 3.2

≥ 3.2, < 5.1

≥ 5.1

N

997

44

413

540

 

Age (year)

57.66 (12.82)

54.36 (13.76)

54.83 (13.02)

60.09 (12.10)

< 0.001

Female, n (%)

777 (77.93%)

36 (81.82%)

339 (82.08%)

402 (74.44%)

0.015

BMI (kg/m2)

23.96 (3.49)

23.97 (3.40)

24.10 (3.55)

23.86 (3.45)

0.561

DD (month)

48.00 (12.00–132.00.00.00)

60.00 (24.00–126.50.00.50)

58.00 (12.00–144.00.00.00)

48.00 (9.00–132.00.00.00)

0.333

Smoking, n (%)

55 (5.52%)

4 (9.09%)

17 (4.12%)

34 (6.30%)

0.196

Drinking, n (%)

18 (1.81%)

1 (2.27%)

7 (1.69%)

10 (1.85%)

0.956

Hypertension, n (%)

323 (32.40%)

13 (29.55%)

115 (27.85%)

195 (36.11%)

0.024

DM, n(%)

93 (9.33%)

7 (15.91%)

27 (6.54%)

59 (10.93%)

0.021

CHD, n(%)

69 (6.92%)

2 (4.55%)

33 (7.99%)

34 (6.30%)

0.485

WBC (*109/L)

6.52 (2.18)

5.65 (2.02)

6.05 (2.02)

6.94 (2.22)

< 0.001

Neut (*109/L)

4.22 (1.81)

3.43 (1.64)

3.77 (1.66)

4.63 (1.83)

< 0.001

Lymph (*109/L)

1.63 (0.59)

1.62 (0.55)

1.65 (0.59)

1.62 (0.59)

0.723

RBC (*1012/L)

3.88 (0.49)

4.02 (0.63)

3.97 (0.48)

3.80 (0.48)

< 0.001

Hb (g/L)

111.07 (17.14)

119.84 (18.34)

114.07 (17.43)

108.06 (16.16)

< 0.001

PLT (*109/L)

291.96 (90.93)

237.18 (54.59)

269.05 (85.71)

313.94 (91.08)

< 0.001

SII

733.10 (460.50–1064.70.50.70)

474.05 (355.80–695.40.80.40)

587.00 (374.90–887.00)

861.35 (623.48–1223.83.48.83)

< 0.001

In SII

6.55 (0.62)

6.16 (0.51)

6.34 (0.60)

6.74 (0.57)

< 0.001

ESR (mm/H)

56.00 (33.00–86.00)

15.00 (8.00–27.50.00.50)

32.00 (23.00–50.00)

82.00 (61.00–103.00.00.00)

< 0.001

CRP (mg/L)

26.01 (7.13–48.02)

3.43

(1.60–8.31)

8.62

(2.94–24.63)

40.99 (24.91–65.25)

< 0.001

RF (IU/mL)

161.80 (47.77–335.83.77.83)

60.25 (24.18–167.65.18.65)

121.30 (37.75–278.60)

207.10 (59.50–424.70.50.70)

< 0.001

ACPA positive n (%)

898 (90.89%)

37 (86.05%)

371 (90.93%)

490 (91.25%)

0.521

APF positive, n (%)

782 (81.04%)

36 (83.72%)

313 (79.64%)

433 (81.85%)

0.629

AKA positive, n (%)

723 (75.00%)

31 (72.09%)

287 (73.21%)

405 (76.56%)

0.461

NSAIDs, n (%)

510 (51.15%)

20 (45.45%)

217 (52.54%)

273 (50.56%)

0.616

Glucocorticoids, n (%)

107 (10.73%)

8 (18.18%)

45 (10.90%)

54 (10.00%)

0.239

Methotrexate, n (%)

204 (20.46%)

12 (27.27%)

116 (28.09%)

76 (14.07%)

< 0.001

Leflunomide, n (%)

195 (19.56%)

18 (40.91%)

80 (19.37%)

97 (17.96%)

0.001

Types of cDMARDs, n (%)

    

< 0.001

0

518 (51.96%)

12 (27.27%)

184 (44.55%)

322 (59.63%)

 

1

357 (35.81%)

18 (40.91%)

169 (40.92%)

170 (31.48%)

 

2

116 (11.63%)

14 (31.82%)

56 (13.56%)

46 (8.52%)

 

3

6 (0.60%)

0 (0.00%)

4 (0.97%)

2 (0.37%)

 

bDMARDs, n (%)

42 (4.21%)

0 (0.00%)

28 (6.78%)

14 (2.59%)

0.002

tsDMARDs, n (%)

23 (2.31%)

2 (4.55%)

16 (3.87%)

5 (0.93%)

0.007

  1. Values are shown as mean ± SD, median (interquartile range) or n (percent).
  2. DAS28ESR disease activity score 28 using erythrocyte sedimentation rate, BMI body mass index, DD disease duration, DM diabetes mellitus, CHD coronary heart disease, WBC white blood cell, Neut neutrophil, Lymph lymphocyte, RBC red blood cell, HB hemoglobin, PLT platelet, SII systemic immune-inflammation index, LnSII natural logarithm systemic immune-inflammation index, ESR erythrocyte sedimentation rate, CRP C-reactive protein, RF rheumatoid factor, ACPA anti-citrullinated protein antibody, AKA anti-keratin antibody, APF anti-perinuclear factor, NSAIDs non-steroidal anti-inflammatory drugs, cDMARDs conventional disease-modifying antirheumatic drugs, bDMARDs biological disease-modifying antirheumatic drugs, tsDMARDs targeted synthetic disease-modifying antirheumatic drugs.
Back to article page